• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California.
| Market Cap | 135.386 Million | Shares Outstanding | 61.82 Million | Avg 30-day Volume | 692.001 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.05 |
| Price to Revenue | 3.9929 | Debt to Equity | 0.0 | EBITDA | 1.056 Million |
| Price to Book Value | 6.1176 | Operating Margin | -7.706200000000001 | Enterprise Value | 75.117 Million |
| Current Ratio | 2.076 | EPS Growth | 0.4 | Quick Ratio | 1.49 |
| 1 Yr BETA | 0.5223 | 52-week High/Low | 0.0 / | Profit Margin | -8.3879 |
| Operating Cash Flow Growth | -108.5444 | Free Cash Flow to Firm (FCFF) TTM | -2.277 Million | Free Cash Flow to Equity (FCFE) TTM | -3.01 Million |
| Altman Z-Score | 5.0153 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
LEONHARDT HARRY J GC & CHIEF COMPLIANCE OFFICER |
|
0 | 2020-09-15 | 0 |
|
No longer subject to file | 2020-07-14 | 0 | |
|
9,188,125 | 2020-07-14 | 0 | |
|
GERGEN MARK J PRESIDENT AND CBO |
|
0 | 2020-07-09 | 0 |
|
0 | 2020-07-09 | 0 | |
|
0 | 2020-07-09 | 0 | |
|
0 | 2020-07-09 | 0 | |
|
0 | 2020-07-09 | 0 | |
|
0 | 2020-07-09 | 0 | |
|
OSTERTAG ERIC CHIEF EXECUTIVE OFFICER |
|
9,316,178 | 2020-07-09 | 0 |
|
MYLET JOHANNA SENIOR VICE PRESIDENT, FINANCE |
|
22,085 | 2020-07-09 | 0 |
|
SPEAR MATTHEW A. CHIEF MEDICAL OFFICER |
|
0 | 2020-07-09 | 0 |
|
INGALLS KERRY D. CHIEF OPERATING OFFICER |
|
0 | 2020-07-09 | 0 |
|
DREYER DAVID C CHIEF FINANCIAL OFFICER |
|
0 | 2014-03-24 | 0 |
|
STEWART BRIAN PRESIDENT & CEO |
|
0 | 2014-03-24 | 0 |
|
0 | 2014-03-24 | 0 | |
|
5,459,517 | 2014-01-09 | 0 | |
|
6,266,666 | 2011-03-29 | 0 | |
|
HAMILTON JOHN A VP & CHIEF OPERATING OFFICER |
|
0 | 2010-08-09 | 0 |
|
No longer subject to file | 2010-06-24 | 0 | |
|
No longer subject to file | 2010-06-24 | 0 | |
|
No longer subject to file | 2010-06-24 | 0 | |
|
No longer subject to file | 2010-06-24 | 0 | |
|
No longer subject to file | 2010-06-24 | 0 | |
|
0 | 2010-06-24 | 0 | |
|
ROSE MARC L CHIEF FINANCIAL OFFICER |
|
0 | 2009-11-24 | 0 |
|
LAY MARY INTERIM CFO |
|
0 | 2009-11-17 | 0 |
|
208,403 | 2009-10-09 | 0 | |
|
551,422 | 2009-07-29 | 0 | |
|
BRUCE DAVID PRESIDENT & CEO |
|
0 | 2009-01-05 | 0 |
|
1,600,000 | 2008-08-01 | 0 | |
|
HORNE WILLIAM B CEO AND CFO |
|
0 | 2008-04-16 | 0 |
|
SPANGLER ARNOLD |
|
0 | 2008-04-16 | 0 |
|
ADAMS WILLIAM M PRESIDENT |
|
0 | 2008-04-16 | 0 |
|
AUGUSTINE DAVID M |
|
6,250 | 2007-01-24 | 0 |
|
6,790,299 | 2007-01-01 | 0 | |
|
50,000 | 2007-01-01 | 0 | |
|
SILVERSTEIN TERESA LYNNE EXECUTIVE VICE PRESIDENT |
|
146,330 | 2006-01-31 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
